Clinical trials: Reduced Ejection Fraction Heart Failure
Heart Failure, Acute Heart Failure
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
Finerenone will be compared to placebo to determine efficacy and safety of treatment in patients hospitalized with acute decompensated heart failure (HF) and mildly reduced or preserved left ventricular ejection fraction.
- Trial name
- REDEFINE-HF (NCT06008197)
- Testing
- Finerenone
- Where
- 356 sites in United States, Argentina and 24 more
- Volunteers
- 5,200 people
- Sponsor
- Colorado Prevention Center
Heart Failure With Reduced Ejection Fraction, Endothelial Dysfunction
Effect of Transcutaneous Vagal Stimulation (TVS) on Endothelial Function and Arterial Stiffness in HFrEF
Heart failure (HF) is the leading cause of hospitalization in the US. Endothelial dysfunction, characterized by the decreased vasodilatory capacity of the vascular endothelium, is rampant in atherosclerotic diseases such as…
- Trial name
- NCT03380156
- Testing
- TVS
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Heart Failure
Real-world Dapagliflozin Treatment in Patients With Heart Failure in Portugal (EVOLUTION-HF)
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages.
- Trial name
- EVOLUTION-HF (NCT05465213)
- Where
- 8 sites in Portugal
- Volunteers
- 283 people
- Sponsor
- AstraZeneca
Heart Failure, Heart Failure and Reduced Ejection Fraction
Selenium Intervention Registry Randomized Trial in Heart Failure
Heart failure is a serious condition in which the heart is unable to pump blood effectively, and it remains a leading cause of hospitalization and death worldwide despite advances in treatment.
- Conditions
- Heart Failure, Heart Failure and Reduced Ejection Fraction, Heart Failure and Mildly Reduced Ejection Fraction, Heart Failure and Preserved Ejection Fraction
- Trial name
- SIRI-HF (NCT07543562)
- Testing
- Selenium Supplement
- Where
- 11 sites in Norway, Sweden
- Volunteers
- 4,326 people
- Sponsor
- Skane University Hospital